Christopher Smith
Partner @ Brandon Capital
Christopher Smith is a Series A investor at Brandon Capital focused on Health Care and Biotechnology. Before joining Brandon Capital Chris was a Business Development Manager with CSL, Australia’s largest pharmaceutical company. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs andR&D enabling platforms. Earlier Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK.Chris is currently a director of; Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera, and Axelia Oncology.Chris has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Immunology at the Walter and Eliza Hall Institute, and an MBA from the University of Cambridge, specializing in innovation and entrepreneurship. Chris is a graduate of the Australian Institute of Company Directors.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Christopher Smith invests in
Stages Christopher Smith invests in
Countries Christopher Smith invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Okogen
|
Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.The company’s efforts are focused on infectious ocular diseases where treatments are either not available or unsatisfactory. | $10M / Series A / Feb 27, 2018 | |
|
Okogen
|
Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.The company’s efforts are focused on infectious ocular diseases where treatments are either not available or unsatisfactory. | $10M / Series A / Feb 27, 2018 |
Co-Investors
About Brandon Capital
Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.
Brandon Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Nave
Partner, Managing Director & Co-Founder
|
|||
Robert Daniels
Venture Partner
|
|||
Stephen Thompson
Partner
|
|||
Bob Soh
Senior Investment Manager
|
|||
|
Christopher Smith
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christopher Smith invest in?
Christopher Smith invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christopher Smith?
Public channels for Christopher Smith include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christopher Smith last invest?
The most recent investment recorded for Christopher Smith closed in Feb 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
